Friday, April 29, 2022

April 29, 2022 at 11:07PM Application Submissions Guidances

This page lists Application Submissions Guidance documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/m0x1PrC

April 29, 2022 at 10:26PM Procleix HIV-1/HCV Assay

Product approval information is indicated for the qualitative detection of human immunodeficiency virus type 1 and/or hepatitis C virus RNA in human plasma from donations of whole blood and blood components for transfusion.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/v7PImcB

April 29, 2022 at 10:20PM ORTHO T. cruzi ELISA Test System

Donor screening test to detect antibodies to T. cruzi in plasma and serum samples from individual human donors, including donors of whole blood, blood components or source plasma, and other living donors. It is also intended for use to screen organ and tissue donors when specimens are obtained while the donor's heart is still beating.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/PpM7UIj

April 29, 2022 at 10:18PM Ortho HCV Version 3.0 ELISA Test System

Product approval information for use as a donor screening test to detect antibodies to hepatitis C virus in plasma and serum samples from individual human donors, including volunteer donors of Whole Blood, blood components, source plasma, and other living donors. It is also intended for use to screen organ donors when specimens are obtained while the donor’s heart is still beating, and in testing blood specimens to screen cadaveric (non-heart-beating) donors. This test is not intended for use on samples of cord blood.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/aTIJjrl

April 29, 2022 at 10:15PM NGI UltraQual Multiplex PCR Assay for HCV, HIV-1, HIV-2 and HBV

The intended use of the National Genetics Institute’s (NGI) UltraQual® Multiplex PCR Assay is to screen source plasma for HCV, HIV-1, HIV-2 and HBV. A maximum number of 512 aliquots from individual donations will be pooled using Tecan Evo robotic pipetting devices. The pools will then be tested using the multiplex assay to detect the presence of hepatitis C virus, human immunodeficiency virus types 1 and 2, and hepatitis B virus. Any pooled samples that test positive for any of these viruses will then be retested, per NGI’s resolution algorithm, to identify the individual positive donation. The assay will discriminate between HCV, HIV-1, HIV-2 and HBV, but will not discriminate between HIV-1 Group M and Group O viruses.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/BkG7lve

April 29, 2022 at 05:36PM Genetic Systems HBsAg EIA 3.0

Product approval information is indicated for detection of Hepatitis B Surface Antigen (HBsAg) in human serum or plasma, and also in cadaveric serum specimens.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/l6O9nvI

April 29, 2022 at 05:10PM Biologics Electronic Reading Room (eFOI)

The Biologics eFOI Reading Room provides access to documents posted throughout the "Vaccines, Blood & Biologics" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/yJZOXxc

April 29, 2022 at 05:04PM COVID-19 Vaccines

FDA has rigorous scientific and regulatory processes in place to facilitate development and ensure the safety, effectiveness and quality of COVID-19 vaccines.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/fFpCWZn

Thursday, April 28, 2022

April 28, 2022 at 09:06PM Premarket Notification Submissions for Blood and Plasma Warmers

Guidance for FDA Reviewers: Premarket Notification Submissions for Blood and Plasma Warmers, CBER, biologics, guidance, reviewer, premarket, PMA, blood, plasma, warmer

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/TnEJwGP

April 28, 2022 at 08:54PM Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components

Guidance for FDA Reviewers: Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components, CBER, biologics, guidance, reviewers, blood, container, collection, processing

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/MOs2Deq

April 28, 2022 at 06:19PM COBAS TaqScreen West Nile Virus Test

Product approval information is indicated for the qualitative detection of West Nile Virus (WNV) RNA in plasma specimens from individual human donors, donors of whole blood and blood components, and other living donors. It is also intended for use in testing plasma specimens to screen organ donors when specimens are obtained while the donor's heart is still beating.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/KdR5gzX

April 28, 2022 at 06:11PM COBAS TaqScreen MPX Test

Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA and Hepatitis B Virus (HBV) DNA Assay

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/huRv6lk

April 28, 2022 at 06:04PM COBAS AmpliScreen HIV-1 Test

Qualitative in vitro test for direct detection of HIV-1 RNA in human plasma from donations of whole blood and blood components for transfusion

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/ZkIKFlX

April 28, 2022 at 06:01PM COBAS AmpliScreen HCV Test

Product approval information for detecting HCV RNA, in conjunction with licensed tests for detecting antibodies to HCV.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/pRaWYdT

April 28, 2022 at 05:57PM COBAS AmpliScreen HBV Test

Product approval information is indicated for:
• Qualitative in vitro test for the direct detection of Hepatitis B Virus (HBV) DNA in human plasma from donations of Whole Blood and blood components for transfusion, and Source Plasma
• Testing individual plasma samples from other living donors and organ donors (when specimens are obtained while the donor's heart is still beating)

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/oJHURk2

April 28, 2022 at 05:48PM Cambridge Biotech HIV-1 Western Blot Kit

Product approval information for urine specimen testing

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/24s0PLw

Wednesday, April 27, 2022

April 27, 2022 at 04:58PM Spikevax and Moderna COVID-19 Vaccine

Information about the Moderna COVID-19 Vaccine and Spikevax

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/mH4paeo

April 25, 2022 at 10:21PM Approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) with Supporting Documents for CBER-Regulated Products

List including applications in alphabetical order by product name for which have approval documents available, and reflects the information as of the approval date.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3glbY4C

April 22, 2022 at 08:42PM NovoSeven

Product approval information is indicated for treatment of bleeding episodes and for the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/9m1EC0O

April 26, 2022 at 07:33PM Micro Typing Systems A/B; MTS A/B/D; MTS A/B/D/Reverse and MTS Monoclonal Rh Phenotype Card

Manufacture of a "Monoclonal Rh Phenotype Card"

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/XlJgjxI

April 25, 2022 at 04:37PM Auszyme Monoclonal

Product approval information is indicated for use to include cadaveric serum specimen testing.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/PZ4JnNe

April 25, 2022 at 04:07PM Anti-B (Murine Monoclonal)

Product information for Anti-B (Murine Monoclonal)

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/udxaZRt

Friday, April 22, 2022

April 22, 2022 at 08:52PM ABBOTT HIVAB HIV-1/HIV-2 (rDNA) EIA

HIVAB HIV-1/HIV-2 (rDNA) EIA is an in vitro enzyme immunoassay for the qualitative
detection of antibodies to human immunodeficiency viruses type 1 and/or type 2
(HIV-1/HIV-2) in human serum, plasma, or cadaveric serum

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/eUGj0XP

April 22, 2022 at 08:50PM ABBOTT HCV EIA 2.0

Product approval information is indicated for cadaveric serum specimen testing.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/T8CpYD0

April 22, 2022 at 08:45PM Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products - Questions and Answers

Questions and answers for potential blood donors and blood recipients are provided. FDA revised its blood donor deferral recommendations for men who have had sex with other men (MSM) as well as those who have hemophilia or related clotting disorders.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3CDSyjf

April 22, 2022 at 08:42PM NovoSeven

Product approval information is indicated for treatment of bleeding episodes and for the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/8kzfrCd

April 22, 2022 at 06:39PM FDA Public Meeting: Identification of Concepts and Terminology for Multi-Component Biomarkers - 03/23/2022

The FDA Center for Drug Evaluation and Research and the FDA Biomarker Working Group will convene a virtual workshop on March 23-24, 1-3 PM (EST) entitled “Identification of Concepts and Terminology for Multi-Component Biomarkers”. The workshop is intended to develop multi-component biomarker concepts and terminology to identify areas of conceptual

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/KlNfROb

April 22, 2022 at 04:29PM Emergency Use Authorization for Vaccines to Prevent COVID-19

This is the Guidance for Industry for the Emergency Use Authorization for Vaccines to Prevent COVID-19. , COVID-19, Coronavirus Disease 2019, Vaccines , CBER, Biologics

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/chUa7md

April 22, 2022 at 02:14PM Workshops, Meetings & Conferences (Biologics)

Information on CBER sponsored or co-sponsored meetings, conferences and workshops about various biologics in order to educate the public and seek the opinion of interested parties.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/4VUiRy6

April 22, 2022 at 01:19PM Annual Patient Engagement & Regenerative Medicine Meeting 2022: An FDA CBER Workshop for Patient Advocates - 05/24/2022

New event page to promote CBER's annual patient engagement and regenerative medicine workshop. The webpage will include information about the event, including the agenda and event details. We would like the event to be featured here: https://ift.tt/MtVHwjX

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/0TilVhO

Thursday, April 21, 2022

April 21, 2022 at 10:19PM Approved Blood Products

Products that are regulated as Biologics License Applications (BLAs), New Drug Applications (NDAS), Premarket Approvals (PMAs), and 510(k)s.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/oOrpXlY

April 21, 2022 at 08:17PM HIZENTRA

Product approval information is indicated for treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/X1TxcVk

April 20, 2022 at 10:13PM Refuse to Accept Policy for 510(k)s

This document explains the procedures and criteria FDA intends to use in assessing whether a 510(k) submission should be accepted for substantive review.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/ZC7HaUP

Wednesday, April 20, 2022

April 20, 2022 at 07:44PM Guidance Recap Podcast | Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products Podcast

The Guidance Recap Podcast provides highlights for FDA guidance documents straight from the authors.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/oODKlgr

Tuesday, April 19, 2022

April 19, 2022 at 09:36PM CANDIN

Submission Tracking Number (STN) BL 103257/5066 has been assigned to your recent supplement to your biologics license application for Candida albicans Skin Test Antigen for Cellular Hypersensitivity, CANDIN®, dated April 5, 2016. Your submission is in the form of a “Supplement – Changes Being Effected” as described under 21 CFR 601.12(c)(5).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/iLR2Bsv

April 19, 2022 at 09:47PM Jobs at the Center for Biologics Evaluation and Research (CBER)

CBER has unique opportunities for individuals with backgrounds in science or administration to fill positions involved in the regulation and research of blood, vaccines and therapeutics.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/iTdb3F4

April 19, 2022 at 07:31PM Antimicrobial Resistance Information from FDA

Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/s8JQIUY

April 19, 2022 at 05:46PM Preguntas y respuestas sobre Comirnaty (Vacuna de ARNm contra el COVID-19)

La FDA llevó a cabo una evaluación exhaustiva de los datos y la información presentados en la Solicitud de Licencia Biológica (BLA, por sus siglas en inglés). para Comirnaty antes de tomar la determinación de que la vacuna es segura y eficaz para prevenir el COVID-19 en personas de 16 años y mayores

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/NG9RZH0

April 18, 2022 at 09:13PM FDASIA Section 705 Annual Reports

Annual Reports published by requirement of FDASIA Section 705

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/kJBREwA

April 19, 2022 at 02:28PM BIMO/Team Biologics/Internet Surveillance/Other

This is the main page for the CBER BIMO/Team Biologics/Internet Surveillance/Other.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/qTvnVXc

Monday, April 18, 2022

April 18, 2022 at 09:09PM 2022 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee

This is the main page for CBER 2022 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/pa8L3Ts

April 18, 2022 at 09:08PM Cellular, Tissue, and Gene Therapies Advisory Committee June 9-10, 2022 Meeting Announcement - 06/09/2022

This is the CBER Cellular, Tissue, and Gene Therapies Advisory Committee June 9-10, 2022 Meeting Announcement.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/zk7n8V4

April 18, 2022 at 09:06PM Devices Guidances

This page lists Medical Device Guidance documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/ZmSVPMX

Friday, April 15, 2022

April 15, 2022 at 10:40PM COVID-19 Vaccines

FDA has rigorous scientific and regulatory processes in place to facilitate development and ensure the safety, effectiveness and quality of COVID-19 vaccines.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/UTFOgiY

April 15, 2022 at 01:53PM Patient Engagement Collaborative

The Patient Engagement Collaborative (PEC) is an advancement in the FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Office of Patient Affairs in the Office of Clinical Policy and Programs (OCPP).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/hu90PZp

April 14, 2022 at 06:55PM Administrative Guidances

This page lists Administrative Guidance documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/IWU7dYB

Wednesday, April 13, 2022

April 13, 2022 at 08:13PM Vascular-Based Biomarkers For Evaluation of Biological Product Safety and Efficacy

The main focus of this research program is to study the mechanisms by which biological products or pathogens alter the functioning or integrity of the vascular system in both vascular endothelial cell culture systems and animal models.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/b0oDp1B

April 13, 2022 at 07:53PM Toward More Effective Treatment of Blood Clotting Disorders: Pharmacogenomic Studies of ADAMTS13 and Related Proteins

A description of Chava Kimchi-Sarfaty's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/UpdbayG

April 13, 2022 at 07:44PM Study of the regulation of blood coagulation by factors VIIa and IXa

A description of Mikhail Ovanesov's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/uizZELF

April 13, 2022 at 03:37PM Clinical Guidances

This page lists Clinical Guidance documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/jy7bZT8

April 13, 2022 at 02:59PM Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability

The purpose of this guidance is to provide recommendations to sponsors developing medical products on the approach for developing a Race and Ethnicity Diversity Plan (referred to as the “Plan”) to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic popu

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/oMbtWSj

April 12, 2022 at 02:10PM Biologics Electronic Reading Room (eFOI)

The Biologics eFOI Reading Room provides access to documents posted throughout the "Vaccines, Blood & Biologics" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/rkB0XTH

April 11, 2022 at 08:43PM Clinical Investigator Inspection List L-P

Contains names, addresses, and other information gathered from inspections of clinical investigators (L-P) who have conducted studies with investigational new drugs or investigational devices reviewed by the Center for Biologics Evaluation and Research (CBER).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/upGP2I1

April 11, 2022 at 08:40PM Clinical Investigator Inspection List Q-S

Clinical Investigator Inspection List from inspections of clinical investigators who have conducted studies with investigational new drugs or investigational devices reviewed by CBER

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/HglLwrF

April 11, 2022 at 08:38PM Clinical Investigator Inspection List T-Z

Clinical Investigator Inspection List from inspections of clinical investigators who have conducted studies with investigational new drugs or investigational devices reviewed by CBER

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/RUrbESD

April 11, 2022 at 07:17PM Vaccines Research

List of Vaccines Research.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/i3nDbBM

April 11, 2022 at 07:16PM Supporting the Production of Safe and Effective Influenza Vaccines

A description of Zhiping Ye's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/SgP31Wy

April 11, 2022 at 06:02PM Development of Quantitative Assays to Evaluate the Safety of Cell Substrates and Vaccines

A description of Keith Peden's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/usr4ZDb

April 11, 2022 at 04:58PM New Approaches to the Development and Evaluation of Vaccines Against Hepatitis Viruses

A description of Marian Major's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/uRHVLch

April 11, 2022 at 04:18PM Section 8500: Compliance

This is the SOPP Section 8500: Compliance main page.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/kO8ye2W

Friday, April 8, 2022

April 08, 2022 at 09:52PM Tissue Notices, Proposed and Final Rules

List of Tissue Notices, Proposed and Final Rules

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/R1kxots

April 08, 2022 at 09:26PM Advanced Technology for Reducing the Risk of Transmission by Transfusion

OBRR performs regulatory evaluation of in vitro diagnostic devices used to screen for infectious microorganisms in blood donations.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/k9Iqlcx

Thursday, April 7, 2022

April 07, 2022 at 06:47PM Janssen COVID-19 Vaccine

Information about the Janssen COVID-19 Vaccine, manufactured by Janssen Biotech Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/TA2jXzd

April 07, 2022 at 06:23PM YESCARTA (axicabtagene ciloleucel)

YESCARTA is a treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/KzgtXGU

April 07, 2022 at 04:05PM Patient Listening Session Summaries

Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Office of Patient Affairs draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/iJytFwY

April 07, 2022 at 04:02PM FDA Patient Listening Sessions

Patient Listening Sessions led by FDA’s Office of Patient Affairs provide an opportunity for medical product Centers to engage with patients, caregivers, and advocates about their experiences and perspectives.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/dSDOfby

April 07, 2022 at 03:00PM Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers

Pharmacology/Toxicology

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/q8gd5Ok

April 07, 2022 at 02:08PM Fast Track Designation Request Performance

The Food and Drug Administration Modernization Act of 1997 (FDAMA) includes Section 112, "Expediting study and approval of fast track drugs." This section mandates the Agency to facilitate the development and expedite review of drugs and biologics intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast track adds to existing programs, such as accelerated approval, the possibility of a "rolling submission" for a marketing application. An important feature of fast track is that it emphasizes the critical nature of close early communication between the FDA and sponsor to improve the efficiency of product development.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/6VUltPR

April 06, 2022 at 06:49PM Vaccine EUA Questions and Answers for Stakeholders

Questions and answers about vaccine Emergency Use Authorizations for stakeholders including industry, health care providers, pharmacists, and state, local, tribal, and territorial governments

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/0LwF1oD

Tuesday, April 5, 2022

April 05, 2022 at 08:02PM FAQs: What happens to EUAs when a public health emergency ends?

Answers to frequently asked questions about what happens to Emergency Use Authorizations (EUAs), and medical products available under EUA, when a public health emergency ends.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/RLFdCIS

April 04, 2022 at 10:25PM Section 8200: Investigational New Drugs (INDs)

This is the SOPP Section 8200: Investigational New Drugs (INDs) main page.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/uJe3590

April 04, 2022 at 10:05PM Section 8100: Communication

This is the CBER SOPP Section 8100: Communication main page.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/fAo4stX

April 04, 2022 at 09:29PM Section 8000: General Information

This is the main page for CBER's SOPP Section 8000: General Information.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/57hVHwc

April 04, 2022 at 09:10PM Postmarketing Reports

Postmarketing Reports

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/wDWPjEI

April 04, 2022 at 09:03PM OCTAGAM

Product approval information is indicated for the treatment of chronicimmune purpura (ITP) in adults

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/51MmxRS

April 04, 2022 at 02:51PM CINRYZE

Product approval information is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2CNeUBy

Friday, April 1, 2022

April 01, 2022 at 07:10PM Vaccines Research

List of Vaccines Research.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/C4TIpWP

April 01, 2022 at 07:02PM Section 9150: Office of Tissues and Advanced Therapies

This is the SOPP Section 9150: Office of Tissues and Advanced Therapies.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/5XnjTe6

April 01, 2022 at 03:35PM Cellular, Tissue, and Gene Therapies Advisory Committee March 10, 2022 Meeting Announcement - 03/10/2022

This is the CBER Cellular, Tissue, and Gene Therapies Advisory Committee March 10, 2022 Meeting Announcement.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/Mleq17p

April 01, 2022 at 02:57PM Give Your Community a Boost: Combatting Misinformation Through Communication and Research

During National Minority Health Month, we highlight the ways in which we are working to improve minority health and health equity.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/EJ8zU2a